FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson announced in a press release.
Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...
The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...
If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
However, in people with mild cognitive impairment, the presence of depressive symptoms was tied to a lower likelihood of amyloid pathology (OR 0.73, 95% CI 0.61-0.89, P =0.001), Oomens and colleagues ...
If you’ve been diagnosed with major depressive disorder or a form of anxiety, your mental health provider may prescribe the ...
While studies have associated Morganella morganii and major depressive disorder before, this study deciphers how they are ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback